tiprankstipranks
Trending News
More News >
Regeneron Pharmaceuticals (REGN)
:REGN
US Market

Regeneron (REGN) Stock Forecast & Price Target

Compare
4,662 Followers
See the Price Targets and Ratings of:

REGN Analyst Ratings

Moderate Buy
23Ratings
Moderate Buy
17 Buy
5 Hold
1 Sell
Based on 23 analysts giving stock ratings to
Regeneron
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

REGN Stock 12 Month Forecast

Average Price Target

$724.35
▲(49.95%Upside)
Based on 23 Wall Street analysts offering 12 month price targets for Regeneron in the last 3 months. The average price target is $724.35 with a high forecast of $900.00 and a low forecast of $535.00. The average price target represents a 49.95% change from the last price of $483.07.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"489":"$489","1182":"$1,182","662.25":"$662.3","835.5":"$835.5","1008.75":"$1,008.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$900.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":724.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$724.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":535,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$535.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[489,662.25,835.5,1008.75,1182],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,490.81,522.2861538461539,553.7623076923077,585.2384615384615,616.7146153846154,648.1907692307692,679.666923076923,711.1430769230769,742.6192307692307,774.0953846153845,805.5715384615385,837.0476923076924,868.5238461538461,{"y":900,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,490.81,508.7746153846154,526.7392307692307,544.7038461538461,562.6684615384615,580.6330769230769,598.5976923076923,616.5623076923077,634.5269230769231,652.4915384615385,670.4561538461538,688.4207692307692,706.3853846153846,{"y":724.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,490.81,494.20923076923077,497.60846153846154,501.0076923076923,504.4069230769231,507.80615384615385,511.2053846153846,514.6046153846154,518.0038461538461,521.4030769230769,524.8023076923077,528.2015384615385,531.6007692307692,{"y":535,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":977.46,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1054.11,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1090.13,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1181.42,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1044.02,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":841.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":760.24,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":710.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":671.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":697.71,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":616.09,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":589.13,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":490.81,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$900.00Average Price Target$724.35Lowest Price Target$535.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on REGN
TipRanks AITipRanks
Not Ranked
TipRanks
$532
Hold
10.13%
Upside
Downgraded
05/31/25
Regeneron's overall stock score reflects strong financial performance and a reasonable valuation. However, bearish technical indicators and mixed earnings call results highlight challenges and uncertainties, balancing the positive financial aspects.
UBS
$633$560
Hold
15.93%
Upside
Reiterated
06/05/25
UBS Remains a Hold on Regeneron (REGN)
Jefferies Analyst forecast on REGN
Akash TewariJefferies
Jefferies
$914$804
Buy
66.44%
Upside
Reiterated
06/04/25
Regeneron: Buy Rating Backed by Promising Pipeline and Market Expansion Potential
RBC Capital Analyst forecast on REGN
Brian AbrahamsRBC Capital
RBC Capital
$662
Hold
37.04%
Upside
Reiterated
06/03/25
RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)
Evercore ISI Analyst forecast on REGN
Cory KasimovEvercore ISI
Evercore ISI
$900
Buy
86.31%
Upside
Reiterated
06/02/25
Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN)
Leerink Partners Analyst forecast on REGN
David RisingerLeerink Partners
Leerink Partners
$686$645
Buy
33.52%
Upside
Reiterated
06/02/25
Regeneron: Buy Rating Reaffirmed Amid Growth Prospects and Attractive Valuation
BMO Capital Analyst forecast on REGN
Evan SeigermanBMO Capital
BMO Capital
$800$600
Buy
24.21%
Upside
Reiterated
06/02/25
Regeneron price target lowered to $600 from $800 at BMO CapitalRegeneron price target lowered to $600 from $800 at BMO Capital
Morgan Stanley Analyst forecast on REGN
Terence FlynnMorgan Stanley
Morgan Stanley
$958$755
Buy
56.29%
Upside
Reiterated
06/02/25
Regeneron (REGN) Gets a Buy from Morgan Stanley
Citi
$700$650
Buy
34.56%
Upside
Reiterated
06/02/25
Buy Rating Maintained for Regeneron Despite Mixed Trial Results, Driven by Promising Pipeline and Growth Prospects
Truist Financial Analyst forecast on REGN
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
06/02/25
Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)
Bernstein
$896$750
Buy
55.26%
Upside
Reiterated
06/02/25
Bernstein Sticks to Its Buy Rating for Regeneron (REGN)
Canaccord Genuity Analyst forecast on REGN
John NewmanCanaccord Genuity
Canaccord Genuity
$850
Buy
75.96%
Upside
Reiterated
06/02/25
Optimistic Outlook on Regeneron Despite Mixed AERIFY Trial Results
TD Cowen
$800
Buy
65.61%
Upside
Reiterated
06/02/25
TD Cowen Keeps Their Buy Rating on Regeneron (REGN)
Bank of America Securities Analyst forecast on REGN
Tim AndersonBank of America Securities
Bank of America Securities
$535
Sell
10.75%
Upside
Reiterated
05/30/25
Cautious Outlook on Regeneron: Mixed Itepekimab Results and Eylea Challenges Drive Sell Rating
Guggenheim Analyst forecast on REGN
Yatin SunejaGuggenheim
Guggenheim
$810
Buy
67.68%
Upside
Reiterated
05/30/25
Regeneron (REGN) Gets a Buy from Guggenheim
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on REGN
TipRanks AITipRanks
Not Ranked
TipRanks
$532
Hold
10.13%
Upside
Downgraded
05/31/25
Regeneron's overall stock score reflects strong financial performance and a reasonable valuation. However, bearish technical indicators and mixed earnings call results highlight challenges and uncertainties, balancing the positive financial aspects.
UBS
$633$560
Hold
15.93%
Upside
Reiterated
06/05/25
UBS Remains a Hold on Regeneron (REGN)
Jefferies Analyst forecast on REGN
Akash TewariJefferies
Jefferies
$914$804
Buy
66.44%
Upside
Reiterated
06/04/25
Regeneron: Buy Rating Backed by Promising Pipeline and Market Expansion Potential
RBC Capital Analyst forecast on REGN
Brian AbrahamsRBC Capital
RBC Capital
$662
Hold
37.04%
Upside
Reiterated
06/03/25
RBC Capital Reaffirms Their Hold Rating on Regeneron (REGN)
Evercore ISI Analyst forecast on REGN
Cory KasimovEvercore ISI
Evercore ISI
$900
Buy
86.31%
Upside
Reiterated
06/02/25
Evercore ISI Sticks to Its Buy Rating for Regeneron (REGN)
Leerink Partners Analyst forecast on REGN
David RisingerLeerink Partners
Leerink Partners
$686$645
Buy
33.52%
Upside
Reiterated
06/02/25
Regeneron: Buy Rating Reaffirmed Amid Growth Prospects and Attractive Valuation
BMO Capital Analyst forecast on REGN
Evan SeigermanBMO Capital
BMO Capital
$800$600
Buy
24.21%
Upside
Reiterated
06/02/25
Regeneron price target lowered to $600 from $800 at BMO CapitalRegeneron price target lowered to $600 from $800 at BMO Capital
Morgan Stanley Analyst forecast on REGN
Terence FlynnMorgan Stanley
Morgan Stanley
$958$755
Buy
56.29%
Upside
Reiterated
06/02/25
Regeneron (REGN) Gets a Buy from Morgan Stanley
Citi
$700$650
Buy
34.56%
Upside
Reiterated
06/02/25
Buy Rating Maintained for Regeneron Despite Mixed Trial Results, Driven by Promising Pipeline and Growth Prospects
Truist Financial Analyst forecast on REGN
Srikripa DevarakondaTruist Financial
Truist Financial
Buy
Reiterated
06/02/25
Truist Financial Reaffirms Their Buy Rating on Regeneron (REGN)
Bernstein
$896$750
Buy
55.26%
Upside
Reiterated
06/02/25
Bernstein Sticks to Its Buy Rating for Regeneron (REGN)
Canaccord Genuity Analyst forecast on REGN
John NewmanCanaccord Genuity
Canaccord Genuity
$850
Buy
75.96%
Upside
Reiterated
06/02/25
Optimistic Outlook on Regeneron Despite Mixed AERIFY Trial Results
TD Cowen
$800
Buy
65.61%
Upside
Reiterated
06/02/25
TD Cowen Keeps Their Buy Rating on Regeneron (REGN)
Bank of America Securities Analyst forecast on REGN
Tim AndersonBank of America Securities
Bank of America Securities
$535
Sell
10.75%
Upside
Reiterated
05/30/25
Cautious Outlook on Regeneron: Mixed Itepekimab Results and Eylea Challenges Drive Sell Rating
Guggenheim Analyst forecast on REGN
Yatin SunejaGuggenheim
Guggenheim
$810
Buy
67.68%
Upside
Reiterated
05/30/25
Regeneron (REGN) Gets a Buy from Guggenheim
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Regeneron

1 Month
xxx
Success Rate
23/36 ratings generated profit
64%
Average Return
+3.44%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.89% of your transactions generating a profit, with an average return of +3.44% per trade.
3 Months
xxx
Success Rate
23/36 ratings generated profit
64%
Average Return
+8.21%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.89% of your transactions generating a profit, with an average return of +8.21% per trade.
1 Year
Christopher RaymondPiper Sandler
Success Rate
27/41 ratings generated profit
66%
Average Return
+9.11%
assigned a buy rating 4 months ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 65.85% of your transactions generating a profit, with an average return of +9.11% per trade.
2 Years
xxx
Success Rate
29/36 ratings generated profit
81%
Average Return
+36.56%
reiterated a xxx
rating 8 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 80.56% of your transactions generating a profit, with an average return of +36.56% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

REGN Analyst Recommendation Trends

Rating
Feb 25
Mar 25
Apr 25
May 25
Jun 25
Strong Buy
21
17
24
25
30
Buy
17
19
22
23
25
Hold
9
8
7
9
10
Sell
3
2
5
5
5
Strong Sell
0
0
0
0
0
total
50
46
58
62
70
In the current month, REGN has received 55 Buy Ratings, 10 Hold Ratings, and 5 Sell Ratings. REGN average Analyst price target in the past 3 months is 724.35.
Each month's total comprises the sum of three months' worth of ratings.

REGN Financial Forecast

REGN Earnings Forecast

Next quarter’s earnings estimate for REGN is $8.53 with a range of $4.25 to $10.25. The previous quarter’s EPS was $8.22. REGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.
Next quarter’s earnings estimate for REGN is $8.53 with a range of $4.25 to $10.25. The previous quarter’s EPS was $8.22. REGN beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.04% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.

REGN Sales Forecast

Next quarter’s sales forecast for REGN is $3.29B with a range of $3.10B to $3.51B. The previous quarter’s sales results were $3.03B. REGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.
Next quarter’s sales forecast for REGN is $3.29B with a range of $3.10B to $3.51B. The previous quarter’s sales results were $3.03B. REGN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year REGN has Outperformed its overall industry.

REGN Stock Forecast FAQ

What is REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron Pharmaceuticals’s 12-month average price target is 724.35.
    What is REGN’s upside potential, based on the analysts’ average price target?
    Regeneron Pharmaceuticals has 49.95% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is REGN a Buy, Sell or Hold?
          Regeneron Pharmaceuticals has a consensus rating of Moderate Buy which is based on 17 buy ratings, 5 hold ratings and 1 sell ratings.
            What is Regeneron Pharmaceuticals’s price target?
            The average price target for Regeneron Pharmaceuticals is 724.35. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $900.00 ,the lowest forecast is $535.00. The average price target represents 49.95% Increase from the current price of $483.07.
              What do analysts say about Regeneron Pharmaceuticals?
              Regeneron Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 23 Wall Streets Analysts.
                How can I buy shares of REGN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis